These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28431665)

  • 21. [Not Available].
    Salvador J; Gaztambide S
    Med Clin (Barc); 2014; 143 Suppl 2():1. PubMed ID: 25326835
    [No Abstract]   [Full Text] [Related]  

  • 22. Gut feelings about diabetes and GLP-1 receptor agonists: lessons to be learnt from studies in functional gastrointestinal disorders.
    Rayner CK; Jones KL; Wu T; Horowitz M
    Diabetes Obes Metab; 2017 Mar; 19(3):309-312. PubMed ID: 27862814
    [No Abstract]   [Full Text] [Related]  

  • 23. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes.
    Thomas MC
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S20-2S27. PubMed ID: 28431667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Pfeffer MA; Claggett B; Probstfield JL
    N Engl J Med; 2016 Mar; 374(11):1095-6. PubMed ID: 26981945
    [No Abstract]   [Full Text] [Related]  

  • 26. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Tsutsumi Y; Tsujimoto Y; Ikenoue T
    N Engl J Med; 2016 Mar; 374(11):1094-5. PubMed ID: 26981946
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of GLP-1 receptor agonists for type 2 diabetes treatment intensification after basal insulin failure.
    Joubert M; Reznik Y
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S34-2S38. PubMed ID: 28431670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of new glucagon-like peptide-1 receptor agonist use in patients with type 2 diabetes during 2014-2019 from a US database: prescriber and patient characteristics.
    Lingvay I; Aroda VR; Honoré JB; Ersbøll AS; Nystrup Husemoen LL; Jensen AB; Sommer Matthiessen K; Kosiborod MN
    J Diabetes; 2023 Feb; 15(2):190-195. PubMed ID: 36796312
    [No Abstract]   [Full Text] [Related]  

  • 29. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J
    Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diabetes: Lixisenatide does not increase rates of CVD events.
    Huynh K
    Nat Rev Cardiol; 2016 Feb; 13(2):63. PubMed ID: 26701217
    [No Abstract]   [Full Text] [Related]  

  • 31. The GLP-1 receptor agonist revolution comes to nephrology.
    Thomas MC; Cooper ME
    Nat Rev Nephrol; 2024 Oct; 20(10):637-638. PubMed ID: 39075285
    [No Abstract]   [Full Text] [Related]  

  • 32. [Not Available].
    Fischli S; Henzen C
    Ther Umsch; 2017; 74(8):433-439. PubMed ID: 29461151
    [No Abstract]   [Full Text] [Related]  

  • 33. GLP-1 Receptor Agonists for Cardiovascular Protection: A Matter of Time.
    Caruso I; Cignarelli A; Laviola L; Giorgino F
    Diabetes Care; 2022 Feb; 45(2):e30-e31. PubMed ID: 35020816
    [No Abstract]   [Full Text] [Related]  

  • 34. [The combination of GLP-1 analogs and SGLT2 inhibitors : new perspectives ?].
    Ritz C; Jaafar J; Philippe J
    Rev Med Suisse; 2017 May; 13(565):1134-1139. PubMed ID: 28639755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Number Needed-to-Treat (NNT): Is it a necessary marker of therapeutic efficiency?
    Monnier L; Colette C; Bonnet F; Owens D
    Diabetes Metab; 2020 Sep; 46(4):261-264. PubMed ID: 32035226
    [No Abstract]   [Full Text] [Related]  

  • 36. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.
    Dicembrini I; Nreu B; Scatena A; Andreozzi F; Sesti G; Mannucci E; Monami M
    Acta Diabetol; 2017 Oct; 54(10):933-941. PubMed ID: 28748377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterizing GLP-1 Receptor Agonist Use in Preadolescent and Adolescent Populations.
    Miller MG; Terebuh P; Kaelber DC; Xu R; Davis PB
    JAMA Netw Open; 2024 Oct; 7(10):e2439887. PubMed ID: 39412809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.
    Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K
    Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Modern antihyperglycaemic agents--what is the patient benefit?].
    Siegmund T
    MMW Fortschr Med; 2016 Apr; 158(7):45-8. PubMed ID: 27071585
    [No Abstract]   [Full Text] [Related]  

  • 40. GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes.
    Do D; Lee T; Peasah SK; Good CB; Inneh A; Patel U
    JAMA Netw Open; 2024 May; 7(5):e2413172. PubMed ID: 38787563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.